No abstract is available for this article. Data Availability Statement Data sharing is not applicable to this article as no datasets were generated or analysed during the current study. References 1, , , et al., “Oral Icotrokinra for Plaque Psoriasis in Adults and Adolescents,” New England Journal of Medicine 393, no. 18 (2025): 1784–1795.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by R. Bissonnette
Harmonizing body surface area assessments between the Eczema Area and Severity Index, SCORing Atopic Dermatitis, and handprint methods utilizing one shared measurement-A proposal to improve efficiency and reduce error in atopic dermatitis trials - Jacobso
DATA AVAILABILITY STATEMENT The data that support the findings of this study are available from the corresponding author upon reasonable request.
ASN002 证明有疗效并可改善AD 炎症
Summary 可用于治疗中度至重度特应性湿疹的药物很少。ASN002是一种新型口服(经口服用)药物,试验表明其可降低各种在皮肤炎症中产生作用的蛋白的活性。在当前研究中,在中度至重度湿疹患者中评估了每天一次持续4 周给药的不同剂量 ASN002 的安全性和疗效,并与安慰剂进行了比较。安慰剂是由与用于制造 ASN002 的基材相同的材料制成的药片,但不含有任何活性药物。共计 27 名患者接受 ASN002 治疗,9 名患者接受安慰剂治疗。通常,ASN002耐药良好,而且引起的副作用有限,更高剂量的 ASN002 未使副作用的频率或严重程度增加。经过 4 周治疗后,接受 ASN002 治疗的患者相比接受安慰剂治疗的患者,其湿疹的严重程度得到更好的改善,而且这些正面效应早在开始治疗后 2 周便已显现。另外,ASN002 治疗还可快速改善瘙痒程度,而且可能导致与炎症相关的血液循环蛋白的水平显著降低。总而言之,令人鼓舞的 ASN002 疗效和安全性特征使得有必要在中度至重度湿疹患者中进一步研究 ASN002。
ASN002 demonstrates efficacy and improves inflammation in AD
Summary Few medicines are available for the treatment of moderate‐to‐severe atopic eczema. ASN002 is a new oral (taken by mouth) drug being tested that has been shown to reduce the activity of various proteins playing a role in skin inflammation. In the present study, the safety and efficacy of different doses of ASN002, administered once daily for 4 weeks, were evaluated and compared to a placebo in patients with moderate‑to‑severe eczema.
Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial
Summary Background Despite unmet need, 15 years have passed since a topical therapy with a new mechanism of action for atopic dermatitis (AD) has been approved. Janus kinase (JAK) inhibitor treatment effect via topical application in patients with AD is unknown. Objectives Tofacitinib, a small‐molecule JAK inhibitor, was investigated for the topical treatment of AD.
The Oral JAK/SYK Inhibitor ASN002 Demonstrates Efficacy and Improves Associated Systemic Inflammation in Patients with Moderate‐to‐Severe Atopic Dermatitis: Results from a Randomised, Double‐Blind, Placebo‐Controlled Study - Bissonnette - - British Journa
Original Article The Oral JAK/SYK Inhibitor ASN002 Demonstrates Efficacy and Improves Associated Systemic Inflammation in Patients with Moderate‐to‐Severe Atopic Dermatitis: Results from a Randomised, Double‐Blind, Placebo‐Controlled Study R.
The oral Janus kinase/spleen tyrosine kinase inhibitor ASN002 demonstrates efficacy and improves associated systemic inflammation in patients with moderate‐to‐severe atopic dermatitis: results from a randomized double‐blind placebo‐controlled study
Summary Background ASN002 is an oral dual inhibitor of Janus kinase and spleen tyrosine kinase, which are involved in the pathogenesis of atopic dermatitis (AD) through their regulatory role on T helper (Th)1, Th2 and Th17/Th22 pathways. Objectives The objectives of this study were to evaluate the efficacy, safety, pharmacokinetics and effects on systemic biomarkers of ASN002 in patients with moderate-to-severe AD.
Efficacy and safety of mirikizumab (LY3074828) in the treatment of moderate‐to‐severe plaque psoriasis: results from a randomized phase II study
Summary Background Inhibiting interleukin (IL)‐23 in patients with psoriasis has demonstrated high levels of skin clearance. Objectives To investigate, in a phase II (AMAF; NCT02899988), multicentre, double‐blind trial, the efficacy and safety of three doses of mirikizumab (LY3074828), a p19‐directed IL‐23 antibody, vs. placebo in patients with moderate‐to‐severe plaque psoriasis.
Tofacitinib for Moderate-to-Severe Chronic Plaque Psoriasis
Appendix 1 F.V. has been a principal investigator, member of a scientific advisory board or speaker for AbbVie, Amgen, Eli Lilly, Janssen, Merck, Novartis and Pfizer Inc. N.J.K. has been an investigator, grant reviewer, speaker or advisory board member for AbbVie, Amgen, Dermira, Celgene, Eli Lilly, Janssen, Merck, Novartis, Pfizer Inc, Prothena, Regeneron, Sun and Valeant.
Tofacitinib in patients with moderate to severe chronic plaque psoriasis: long‐term safety and efficacy in an open‐label extension study
Tofacitinib is an oral Janus kinase inhibitor. Final safety and efficacy data from an open‐label extension study of tofacitinib in psoriasis are reported. To evaluate the long‐term safety and durability of efficacy of tofacitinib in adults with moderate to severe chronic plaque psoriasis.
Tofacitinib in patients with moderate‐to‐severe chronic plaque psoriasis: long‐term safety and efficacy in an open‐label extension study
The median duration of treatment in the LTE was 35·6 months (tofacitinib 10 mg q12h: 32·5 months; 5/10 mg q12h: 38·9 months). By month 54, fewer than 100 patients remained in the study, as patients entered the LTE at different times, and therefore may not have reached month 54, at the time of study termination. In total, 1327 patients were discontinued as a result of study termination and 1523 patients were discontinued for other reasons (Fig. 1 ).
JAK inhibitors appear to have a bright future in the treatment of atopic dermatitis
Forgot your password? Enter your email address below. If your address has been previously registered, you will receive an email with instructions on how to reset your password. If you don't receive an email, you should register as a new user Please check your email for your password reset instructions.
JAK inhibitors appear to have a bright future in the treatment of atopic dermatitis
Previous article in issue: Safety gains don't translate into reduced costs or increased QALYs for doxycycline compared with prednisolone for patients with bullous pemphigoid Previous article in issue: Safety gains don't translate into reduced costs or increased QALYs for doxycycline compared with prednisolone for patients with bullous pemphigoid
Persistence of interleukin (IL)-17A+ T lymphocytes and IL-17A expression in treatment-resistant psoriatic plaques despite ustekinumab therapy
Previous article in Early View: Mutational analysis of 29 patients with autosomal-recessive woolly hair and hypotrichosis: LIPH mutations are extremely predominant in autosomal-recessive woolly hair and hypotrichosis in Japan Previous article in Early View: Mutational analysis of 29 patients with autosomal-recessive woolly hair and hypotrichosis: LIPH mutations are extremely predominant in autosomal-recessive woolly hair and hypotrichosis in Japan
Secukinumab Sustains Good Efficacy and Favourable Safety in Moderate to Severe Psoriasis up to 3 Years of Treatment: Results from A Double-Blind Extension Study - Bissonnette - 2017 - British Journal of Dermatology - Wiley Online Library
Secukinumab has demonstrated significant efficacy with a good safety profile through 1 year in plaque psoriasis. Given the chronic nature of this disease, long-term follow-up is needed to fully evaluate psoriasis therapies. Subjects completing 52 weeks of secukinumab treatment in the SCULPTURE core study entered an extension in which they continued the same double-blind regimens.
Increase in coronary atherosclerosis severity and the prevalence of coronary artery mixed plaques in patients with psoriasis
Research LetterIncrease in coronary atherosclerosis severity and the prevalence of coronary artery mixed plaques in patients with psoriasisAuthorsR. Bissonnette,Department of Dermatology, Innovaderm Research Inc., Montreal, QC, CanadaSearch for more papers by this authorF. Cademartiti,Montreal Heart Institute, Université de Montréal, Montréal, QC, CanadaSearch for more papers by this authorE.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with R.
Contact R., search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack